The Trials Were Always There — Patients Just Couldn’t Find Them
This structural problem calls for a structural solution, requiring no new science, regulation, or data.
Ayble Health Secures $16M for Virtual Digestive Health Clinic
Ayble Health’s Series A round was led by Neon, with participation from Unum Ventures, Upfront Ventures, M13, Cleveland Clinic Ventures, DigiTx and Accomplice.
Ultragenyx Gene Therapy Is First Approved Treatment for Rare Neuro Disease Sanfilippo
Ultragenyx Pharmaceutical’s Fayuvi is now the first FDA-approved therapy for the underlying cause of Sanfilippo syndrome type A, an ultra-rare inherited neurological disorder. It’s the second approved gene therapy for Ultragenyx, which specializes in rare disease medicines.
CMS Broadens ACCESS Model to New Chronic Conditions
CMS will expand its ACCESS model starting in spring 2027 to cover heart failure, COPD, substance use disorders and tobacco cessation. The outcomes-based payment model, which launched in July with 160 participating providers, will now make roughly three in four Medicare beneficiaries eligible for at least one track.
Extending ADHD Coverage for the Entire Active Day
The next evolution in ADHD therapy needs to focus not only on drug efficacy but also on how treatment aligns with the ever-busy and demanding lives of patients, families, and caregivers.